I can see why you are a little confused after ATH announced they had opened enrollment in NZ for the phase2 clinical trial. Now this 1 year preclinical. Raises the question of how other P3 NSA end points for trials currently in progress in the US have identified. On June 2 the headline very clearly was the phase2 had been launched. ATH need to clarity IMO. I can understand how an investor who bought in on the June 2 announcement could be a little peeved if the trial has now been set back a year, A biomuse natural history study has already been completed and data presented.
ATH Price at posting:
1.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)